Quick Answer
Ginkgo Focus Meta-Analysis has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: Efficacy of plant extracts in heart failure patients: a systematic review and network meta-analysis.
Key Takeaways
- 01Efficacy of plant extracts in heart failure patients: a systematic review and network meta-analysis. [Tang T (2026)]
- 02In addition, an overview of systematic reviews synthesized the broader EGb 761 evidence base across indications and highlighted that conclusions require caution given the methodological limitations of many reviews []. [Yang YoungSoon (2026)]
- 03Real-world observational analyses have also reported associations between prescriptions of Ginkgo leaf extract and reduced risk of dementia severity progression, albeit with the inherent limitations of non-randomized designs []. [Yang YoungSoon (2026)]
- 04Accordingly, this review revisits the historical evidence base with explicit attention to heterogeneity and methodological design, and then examines biomarker-confirmed AD-spectrum studies as a potential pivot point. [Yang YoungSoon (2026)]
The current Migaku evidence database contains 2 reusable source documents for Ginkgo Focus Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation.
- Efficacy of plant extracts in heart failure patients: a systematic review and network meta-analysis. [Tang T (2026); evidence level 1]
- In addition, an overview of systematic reviews synthesized the broader EGb 761 evidence base across indications and highlighted that conclusions require caution given the methodological limitations of many reviews []. [Yang YoungSoon (2026); evidence level 3]
- Real-world observational analyses have also reported associations between prescriptions of Ginkgo leaf extract and reduced risk of dementia severity progression, albeit with the inherent limitations of non-randomized designs []. [Yang YoungSoon (2026); evidence level 3]
- Accordingly, this review revisits the historical evidence base with explicit attention to heterogeneity and methodological design, and then examines biomarker-confirmed AD-spectrum studies as a potential pivot point. [Yang YoungSoon (2026); evidence level 3]
- 1 2 Alzheimer’s disease (AD) remains the most common cause of dementia and continues to impose a major burden on patients, caregivers, and healthcare systems []. [Yang YoungSoon (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources
- Efficacy of plant extracts in heart failure patients: a systematic review and network meta-analysis.
- Ginkgo Biloba for Alzheimer’s Disease: From Mixed Dementia Trials to Biomarker-Confirmed Mild Cognitive Impairment—What Have We Learned over Two Decades, and Is There Finally a Bit of Hope?